Clinical Trials in Yichang, Hubei
15 recruiting
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 2
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
Pulmonary Disease, Chronic Obstructive
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.195 enrolled29 locationsNCT07252908
Recruiting
Not Applicable
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
Liver Cancer
JIANGSU SHENMING Medical Technology CO., Ltd216 enrolled15 locationsNCT07356531
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Phase 1
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Bambusa Therapeutics68 enrolled11 locationsNCT07288554
Recruiting
Phase 2
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal (Jiangsu) Pharmaceutical Co., Ltd.66 enrolled15 locationsNCT07154264
Recruiting
Phase 2
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Mabwell (Shanghai) Bioscience Co., Ltd.360 enrolled51 locationsNCT07292714
Recruiting
Not Applicable
Burst Stimulation for Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Zhibing Lu240 enrolled3 locationsNCT07281898
Recruiting
Phase 2Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.226 enrolled53 locationsNCT06378138
Recruiting
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
Cognitive Dysfunction
Tongji Hospital5,000 enrolled21 locationsNCT07128186
Recruiting
Not Applicable
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
Type 2 Diabetes
State Key Laboratory of Subhealth Intervention Technology120 enrolled3 locationsNCT05439226
Recruiting
Not Applicable
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
Metabolic Dysfunction-Associated Steatotic Liver DiseaseType 2 Diabetes Mellitus
State Key Laboratory of Subhealth Intervention Technology120 enrolled3 locationsNCT07083336
Recruiting
Phase 3
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukaemia
Zhongnan Hospital154 enrolled11 locationsNCT06345365